Juno Pharmaceuticals Pty Ltd v Janssen Pharmaceutica NV

Link copied
Case Copied 35 min read

IP AUSTRALIA

AUSTRALIAN PATENT OFFICE

Juno Pharmaceuticals Pty Ltd v Janssen Pharmaceutica NV [2024] APO 48

Patent:2008340101

Title:Dosing regimen associated with long acting injectable paliperidone esters

Patentee:Janssen Pharmaceutica NV

Opponent:Juno Pharmaceuticals Pty Ltd

Delegate:Dr S. J. Smith

Decision Date:  4 December 2024

Hearing Date:  14 August 2024, by videoconference

Catchwords:  PATENTS – section 104 – opposition to amendments – allowability under section 102 – sections 102(1), 102(2)(a), 102(2)(b) – what arises as a result of the amendment – amendments allowed – costs awarded against the opponent

Representation:                   Counsel for the patentee: Cynthia Cochrane SC

Patent attorney for the patentee: Katrina Crooks of Spruson & Ferguson Lawyers

Counsel for the opponent: Marcus Fleming

Patent attorney for the opponent: Paul Jones, Sarah Couper, Rosemary Manhire-Heath and Ellen Reid of Jones Tulloch

IP AUSTRALIA

AUSTRALIAN PATENT OFFICE

Patent:2008340101

Title:Dosing regimen associated with long acting injectable paliperidone esters

Patentee:Janssen Pharmaceutica NV

Date of Decision:                4 December 2024

DECISION

The opposition is unsuccessful.  Subject to appeal, I allow the amendments.

I award costs according to Schedule 8 against the opponent, Juno Pharmaceuticals Pty Ltd.

REASONS FOR DECISION

Background

  1. Patent 2008340101 (the patent) was filed by Janssen Pharmaceutical NV (the patentee) on 17 December 2008 under the provisions of the Patent Cooperation Treaty as international application PCT/EP2008/067738 and claiming an earliest priority date of 19 December 2007.  The patent was granted on 3 December 2015.

  2. On 22 February 2023 the patentee sought leave to amend the specification, which amendments were subsequently superseded by further amendments filed on 17 May 2023.  Leave to amend was granted and the amendments were advertised for opposition purposes on 15 June 2023. 

  3. Juno Pharmaceuticals Pty Ltd (the opponent) filed a notice of opposition to the allowance of the amendments on 15 August 2023 and a statement of grounds and particulars on 15 September 2023.  The statement of grounds and particulars identifies as grounds of opposition to the amendments failure to comply with ss 102(3), 102(2)(a), 102(2)(b) and 102(1).  At the hearing grounds of ss 102(2)(a), 102(2)(b) and 102(1) were pressed.

  4. Evidence in support consists of a declaration by Professor Nicholas Keks dated 10 January 2024 (Keks) together with annexures NK-1 to NK-10 and a declaration by George Moksdi dated 10 January 2024 (Moksdi).  Professor Keks was, as at the priority date, a clinical psychiatrist diagnosing and treating patients for schizophrenia or schizoaffective disorders.[1]  He was also involved in clinical research projects and lectured to psychiatry students.[2]  Mr Moksdi gives evidence as a patent and literature searcher of the publication date of various documents[3] but his evidence is not relied on by the opponent.  Evidence in answer consists of a declaration by Professor Bruce Sugriv Singh dated 4 April 2024 (Singh) together with exhibits BSS-1 to BSS-5.  Professor Singh has many years of experience as a medical practitioner specialising in psychiatry.[4]  No evidence in reply was filed.  I am satisfied that both Professor Keks and Professor Singh have backgrounds that enable them to…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Juno Pharmaceuticals Pty Ltd v Janssen Pharmaceutica NV and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2024] APO 48
Decision Date

CaseChat Overview and Summary

In this case, the court dealt with an opposition to amendments proposed by the patent holder, Janssen Pharmaceutica NV, to its patent for a pharmaceutical compound. The opposition was brought by Juno Pharmaceuticals Pty Ltd, which argued that the amendments were not allowable under the relevant provisions of the Patents Act 1990 (Cth). The case was heard by the Federal Court of Australia.

The central legal issue before the court was whether the proposed amendments to the patent specification were allowable under section 102 of the Patents Act. Specifically, the court had to determine if the amendments met the criteria set out in section 102(2)(a) and (b), which relate to the content that 'arises' from the original application as filed. The court also needed to decide whether the amendments were allowable under section 104, which pertains to the opposition process and the grounds upon which an opponent may challenge the patent.

The court found that the amendments proposed by Janssen were allowable under the relevant sections of the Act. It held that the content in question did arise from the original application and met the criteria of section 102(2)(a) and (b). Furthermore, the court ruled that the opposition to the amendments was not valid under section 104, as the grounds for opposition did not meet the statutory requirements. Consequently, the court allowed the amendments and ordered Juno Pharmaceuticals to pay the costs of the proceedings.

The final orders of the court included the allowance of the patent amendments and the awarding of costs to Janssen Pharmaceutica NV against Juno Pharmaceuticals Pty Ltd. This decision underscored the importance of meeting the statutory criteria for patent amendments and the consequences of an unsuccessful opposition under the Patents Act.

Orders

Orders of the court

Full text does not contain this section.

Background

Background to the litigation

Full text does not contain this section.

Evidence

Evidence Before The Court

Full text does not contain this section.

Decision

Reasons for decision

Full text does not contain this section.

Ratio Decidendi

Legal Principle Established

Full text does not contain this section.